Objectives. To establish the incidence of adverse drug reactions (ADRs) in oncology patients hospitalised at a tertiary referral adult cancer hospital and identify areas where intervention strategies may effectively reduce their impact.
Design. A prospective study was conducted in November and December 1998 at the Peter MacCallum Cancer Institute (PMCI), Melbourne, Australia. Pharmacists identified patients who had experienced an ADR contributing to the admission or occurring during the episode of care.
Outcome measures. An assessment was made of causality, as definite, probably or possibly. The severity of the ADR was assessed as mild, moderate or severe.
Results. Twenty-six admissions (9.6%) were related to drug therapy. One hundred and thirty-four ADRs occurred in 86 inpatient episodes of care (31.6% of admissions). One hundred and four ADRs (60.8%) were associated with active therapy for malignancy or infection. Supportive therapy, including analgesics and antiemetics, were implicated in 67 (39.2%) adverse events. Pharmacists rated the majority of reactions as definitely associated with the implicated drug and the majority of at least moderate severity.
Discussion. Drug therapy contributed to 9.6% of admissions. This is higher than in other Australian studies. The majority of ADRs identified were associated with active therapy for malignancy or infection. These adverse effects are not unexpected in the setting of aggressive therapy. Other potentially preventable ADRs may be overlooked in the context of the more severe and life-threatening events occurring simultaneously.
Conclusion. Approximately 37.5% of patients admitted to PMCI experienced an ADR. Many of these events may have been prevented using simple intervention strategies. There is an opportunity for clinical pharmacists to ensure preventive measures are instituted, thereby improving patient outcomes.
Gurney H.Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14:2590-2611.
2.
Einarson TR.Drug-related hospital admissions. Ann Pharmacother. 1993;27:832-840.
3.
Easton KL, Parsons BJ, Starr M, Brien JE.The incidence of drug-related problems as a cause of hospital admissions in children. Med J Aust. 1998;169:356-359.
4.
Leape LL, Brennan TA, Laird N, et al.The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med. 1991;324:377-384.
5.
Larmour I, Dolphin RG, Baxter H, Morrison S, Hooke DH, McGrath BP.A prospective study of hospital admissions due to drug reactions. Aust J Hosp Pharm. 1991;21:90-95.
6.
Dartnell JGA, Anderson RP, Chohan V, Galbraith KJ, Lyon MEH, Nestor PJ, et al.Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs. Med J Aust. 1996;164:659-662.
7.
Requirements for Adverse Reactions Reporting. Geneva: World Health Organisation; 1975.
8.
Brennan TA, Leape LL, Laird N, Herbert L, Localio AR, Lawthers AG, et al.Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. N Engl J Med. 1991;324:370-376.
9.
Gholami K, Shalviri G.Factors associated with preventability, predictability and severity of adverse drug reactions. Ann Pharmacother. 1999;33:236-240.
10.
Nelson KM, Talbert RL.Drug-related hospital admissions. Pharmacotherapy. 1996;16:701-707.
11.
Naranjo CA, Busto V, Sellers EM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245.
12.
Hartwig SC, Siegel J, Schneider PJ.Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229-2232.
13.
Schumock GT, Thornton JPFocusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538-538.
14.
Australian Adverse Drug Reactions Bulletin, Canberra: TGA, Adverse Drug Reactions Advisory Committee; 1999.
15.
National Hospital Morbidity Data Collection—Australia (excluding Northern Territory); 1992/93.
